Loading cancer entity…
Loading cancer entity…
Clinical trials
806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04611685 | Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas | unknown | N/A | 202 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02113800 |
| completed |
| Phase 2 |
| 40 |
| AIO-Studien-gGmbHOTHER |
| 1 |
| Oct 28, 2020 |
| clinicaltrials |
| NCT04334837 | Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) | approved for marketing | — | — | Curium US LLCINDUSTRY | 0 | Oct 9, 2020 | clinicaltrials |
| NCT02698410 | Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.(ATLANT) | completed | Phase 2 | 40 | IpsenINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT00843531 | RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT04557137 | Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia | unknown | — | 100 | University of AarhusOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04129255 | Octreotide LAR in the Induction of Immunologic Response in NENs Patients(CSMS99) | completed | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02315625 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03883776 | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors | completed | Phase 1 | 12 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03562091 | Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel(OPERA) | completed | — | 115 | IpsenINDUSTRY | 1 | Aug 28, 2020 | clinicaltrials |
| NCT03881306 | DEBOXA for Inoperable NET Liver Metastases | unknown | Phase 1 / Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04039516 | Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy(CHARRT) | unknown | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 0 | Aug 4, 2020 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02402062 | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | completed | Phase 2 | 17 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04107480 | PRolaCT - Three Prolactinoma RCTs | unknown | Phase 4 | 880 | Leiden University Medical CenterOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03923777 | Active Surveillance in Early Lung Cancer(ACTION-Lung) | unknown | N/A | 26 | University of Vermont Medical CenterOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03197012 | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | completed | Early Phase 1 | 10 | Thomas HopeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02730104 | Community-based Neuroendocrine Tumor (NET) Research Study | completed | — | 100 | IpsenINDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04440956 | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours | completed | Early Phase 1 | 10 | Clarity Pharmaceuticals LtdINDUSTRY | 0 | Jun 22, 2020 | clinicaltrials |
| NCT02067988 | Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study(HEPAR_Plus) | completed | Phase 2 | 34 | UMC UtrechtOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04425954 | Evaluation of Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery | completed | — | 14 | Federico II UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT02788565 | Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours(STREET) | completed | — | 156 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03112694 | Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors | completed | — | 93 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03840720 | The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET | completed | — | 20 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04336839 | Portal Vein Resection in Pancreatic Neuroendocrine Tumours(PVNET) | unknown | — | 40 | Royal Free Hospital NHS Foundation TrustOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04029428 | Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression(POLNETS_PRRT) | unknown | Phase 2 | 150 | University of Warmia and MazuryOTHER | 1 | Apr 1, 2020 | clinicaltrials |
| NCT00171873 | Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | completed | Phase 3 | 85 | Carmen Schade-BrittingerOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT02841865 | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria(CRIPNET) | completed | — | 104 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03457389 | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | unknown | N/A | 68 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT03474601 | Seoul National University Pituitary Disease Cohort Study(SNU-PIT) | unknown | — | 1,600 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | completed | Phase 1 | 122 | PharmaMarINDUSTRY | 2 | Mar 9, 2020 | clinicaltrials |
| NCT04296149 | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe(RADIONET) | completed | Phase 2 | 5 | European Institute of OncologyOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03422029 | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | unknown | Phase 2 | 20 | Peking UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT00501540 | Lithium for Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02357498 | Transsphenoidal Extent of Resection Study(TRANSSPHER) | completed | N/A | 260 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02727686 | Post-Operative Water Load Following Transsphenoidal Pituitary Surgery | completed | N/A | 30 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01967537 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | completed | Phase 2 | 341 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01476592 | A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | completed | N/A | 7 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02125474 | Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate | completed | N/A | 39 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 3, 2020source: clinicaltrials